Business Summary
Logo Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Number of employees : 300 people.
Sales per Business
Therapeutic Drugs50.12100%45.61100% -9%
USD in Million
Sales per region
United States45.4999.7%
USD in Million
Name Title Age Since
Peter S. Greenleaf President, Chief Executive Officer & Director 51 2019
Joseph M. Miller Chief Financial Officer 47 2020
Robert B. Huizinga, Dr. Executive Vice President-Research 56 2020
Neil Solomons, Dr. Chief Medical Officer 53 2013
Rashieda Gluck Senior Vice President-Global Clinical Operations - 2018
Simrat Randhawa Senior Vice President-Clinical & Medical Affairs - 2019
Stephen P. Robertson Secretary 39 2014
Glenn Schulman, Dr. Senior VP-Communications & Investor Relations - -
Fran Lynch Vice President-Sales - 2020
Michael R. Martin Chief Business Officer 49 2020
Members of the board
Name Title Age Since
George M. Milne, Dr. Chairman 77 2019
David R. W. Jaynee, Dr. Independent Director 64 2015
Joseph P. Hagan Independent Director 52 2018
Daniel G. Billen, Dr. Independent Director 67 2019
R. Hector MacKay-Dunn Independent Director 70 2019
Jill Leversage Independent Director 64 2019
Timothy Walbert Independent Director 54 2020
Brinda Balakrishnan, Dr. Independent Director 41 2021
Peter S. Greenleaf President, Chief Executive Officer & Director 51 2019
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 141,741,580 132,766,370 93.7% 0 0.0% 93.7%
ILJIN Holdings Co., Ltd. 6,832,320 4.82%
Fidelity Management & Research Co. LLC 5,291,226 3.74%
Consonance Capital Management LP 4,621,325 3.26%
NEA Management Co. LLC 3,969,834 2.80%
OrbiMed Advisors Private Equity 3,714,404 2.62%
APG Asset Management NV 3,450,357 2.44%
Polar Capital LLP 3,312,723 2.34%
Morgan Stanley & Co. LLC 2,597,187 1.83%
Bellevue Asset Management AG 2,405,825 1.70%
Susquehanna Financial Group LLLP 1,923,005 1.36%
Company contact information
Aurinia Pharmaceuticals, Inc.
4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8

Phone : +1.250.744.2487
Fax : +1.250.744.2498
Web :
Brand Portfolio
In partnership
More brands of Aurinia Pharmaceuticals Inc.